Benzinga | Jan 22, 2021 07:07AM EST

RBC Capital Maintains Sector Perform on BioCryst Pharmaceuticals, Raises Price Target to $9

RBC Capital maintains BioCryst Pharmaceuticals (NASDAQ:BCRX) with a Sector Perform and raises the price target from $7 to $9.